ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that it will host an R&D event on Thursday, January 26, 2023 in New York City from 9-11:30 a.m. ET. The event will highlight key aspects of Ventyx’s clinical-stage and discovery programs.
Participating in the presentations and discussions will be members of the Ventyx Executive Team and Clinical Advisors, including:
A live webcast of the event will be available in the “Investors” section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event.
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.
Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
ANACONDA, Mont., May 19, 2025 /PRNewswire/ -- Community Hospital of Anaconda ("CHA") is providing notice…
SAN FRANCISCO, May 19, 2025 /PRNewswire/ -- Following its recent FDA approval, Teal Health® announced the…
Free program will provide access to affordable medications to Sheriffs' employees across the nation PLYMOUTH,…
Collaboration Blends Advanced Cloud Technologies, Open-Source Collaboration, and Data Science Integration to support UCB's development pipeline…
AI-driven robotics platform reduces drug formulation development time from years to months SACRAMENTO, Calif., May…
Among the highlights were a completely unique whole-body 8 ch-parallel transmit coil on the 5T…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
